In the 2016 WHO classification, the presence or absence of the molecular marker isocitrate dehydrogenase mutation (IDHmut) defines two different types of GBM (secondary and primary, respectively), with different prognosis, not used in the old classification. The gene discussed is IDH3A; the disease is glioblastoma.